Patents by Inventor Shankar M. Singh

Shankar M. Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
    Publication number: 20040082556
    Abstract: Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.
    Type: Application
    Filed: November 26, 2002
    Publication date: April 29, 2004
    Applicant: Endorecherche, Inc.
    Inventors: Fernand Labrie, Alain Belanger, Sylvain Gauthier, Van Luu-The, Yves Merand, Donald Poirier, Louis Provencher, Shankar M. Singh
  • Inhibitors of type 5 and type 3 17&bgr;-hydroxysteroid dehydrogenase and methods for their use
    Patent number: 6541463
    Abstract: Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 1, 2003
    Assignee: Endorecherche, Inc.
    Inventors: Fernand Labrie, Alain Belanger, Sylvain Gauthier, Van Luu-The, Yves Merand, Donald Poirier, Louis Provencher, Shankar M. Singh
  • Antiandrogens
    Patent number: 6015806
    Abstract: Androgen nucleus derivatives having specified substituents at the 17.alpha. position are disclosed for use as antiandrogens for the treatment of androgen-dependent diseases. In some preferred embodiments, the compound ##STR1## is formulated together with pharmaceutically acceptable diluent or carrier for topical use in the treatment of androgen-dependent diseases associated with the skin.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 18, 2000
    Assignee: Endorecherche
    Inventors: Fernand Labrie, Yves Merand, Shankar M. Singh
  • Inhibitors for testosterone 5.alpha.-reductase activity
    Patent number: 5494914
    Abstract: Inhibitors of testosterone 5.alpha.-reductase activity, for example those of formula: ##STR1## wherein novel substituents are provided at the R.sup.4, R.sup.6, R.sup.7, R.sup.17.alpha. and/or R.sup.17.beta. positions are useful for the treatment of diseases whose progress is aided by activation of androgen receptors, e.g., prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia and the like.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: February 27, 1996
    Assignee: Endorecherche
    Inventors: Fernand Labrie, Yves M. Merand, Shankar M. Singh